Examkin

Soru

Zorluk: KolayMonitoring and Treatment Evaluation

A 3434-year-old man comes to the clinic for a routine follow-up visit. He was diagnosed with schizophrenia 33 months ago and was started on olanzapine. The patient reports that his auditory hallucinations have completely resolved and he is tolerating the medication well, although he has noticed an increased appetite. His blood pressure is 128/82128/82 mmHg, pulse is 7878/min, and body mass index is 2929 kg/m 2^2 (up from 2626 kg/m 2^2 at baseline). Physical examination shows no abnormalities. Which of the following is the most appropriate next step in monitoring this patient's pharmacotherapy?

  1. Obtain a fasting lipid panel and fasting blood glucoseCevap
  2. B
    Obtain an absolute neutrophil count
  3. C
    Advise the patient to immediately discontinue olanzapine
  4. D
    Schedule a dual-energy x-ray absorptiometry scan
  5. E
    Order a non-contrast CT scan of the head

Cevap

The correct next step is to obtain a fasting lipid panel and fasting blood glucose to evaluate for medication-induced metabolic syndrome.
The correct answer involves evaluating for metabolic derangements. Olanzapine is a second-generation antipsychotic (SGA) that is highly efficacious but carries one of the highest risks for metabolic syndrome among SGAs, comparable to clozapine. The patient's significant weight gain over just 33 months strongly signals the onset of metabolic side effects. Current guidelines mandate routine monitoring of body weight, waist circumference, blood pressure, fasting plasma glucose, and fasting lipid profiles at baseline, 1212 weeks, and annually thereafter for patients on these medications.

Adım Adım Çözüm

1
Assess the patient's current clinical status and medication regimen.
The patient has well-controlled schizophrenia on olanzapine but exhibits significant weight gain (increase in BMI of 3 kg/m^2 over 3 months).
Establishing the clinical response and identifying new physical changes guides appropriate follow-up testing.
2
Identify the specific adverse effect profile of the prescribed medication.
Olanzapine is a second-generation antipsychotic known to have a very high risk of inducing metabolic syndrome.
Different antipsychotics have varying side effect profiles that dictate specific routine monitoring requirements.
3
Determine the guideline-directed monitoring tests for this adverse effect.
Guidelines recommend checking fasting blood glucose (or HbA1c) and a fasting lipid panel at baseline, at 12 weeks, and annually thereafter.
Early detection of dyslipidemia and hyperglycemia allows for timely intervention, such as lifestyle modifications or switching to a metabolically neutral antipsychotic.

Anahtar Kavram

Patients taking second-generation antipsychotics, particularly olanzapine and clozapine, require routine monitoring for metabolic syndrome, which includes serial assessments of weight, fasting blood glucose, and fasting lipid panels.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru